Capital Asset Advisory Services’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Capital Asset Advisory Services’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-506	Closed	-$24K	–	724
2021 Q3	$24K	Hold	506	–	–	﹤0.01%	543
2021 Q2	$26K	Hold	506	–	–	﹤0.01%	570
2021 Q1	$25K	Hold	506	–	–	﹤0.01%	545
2020 Q4	$26K	Hold	506	–	–	﹤0.01%	794
2020 Q3	$22K	Sell	506 -50	-9%	-$2.19K	﹤0.01%	431
2020 Q2	$24K	Hold	556	–	–	0.01%	448
2020 Q1	$23K	Sell	556 -100	-15%	-$4.26K	0.01%	393
2019 Q4	$31K	Buy	+656	New	+$26K	0.01%	456

Other funds holding XPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Centaurus Financial Anaheim, California $2.59B AUM 31.63% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Capital Asset Advisory Services's XPH Position: Q4 2021 in Review

Capital Asset Advisory Services sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q4 2021, closing a stake of 506 shares — an estimated $24K sold.

Capital Asset Advisory Services first reported a position in XPH in Q4 2019 and held it in 8 quarters. The position peaked at $31K in Q4 2019. 77 funds tracked by Wall St. Rank hold XPH as of Q4 2021.

Capital Asset Advisory Services reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q4 2021 after selling out during the quarter.
Capital Asset Advisory Services sold 506 State Street SPDR S&P Pharmaceuticals ETF shares in Q4 2021, an estimated $24K.
Capital Asset Advisory Services first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2019 and held it in 8 quarters.
Capital Asset Advisory Services's State Street SPDR S&P Pharmaceuticals ETF position peaked at $31K in Q4 2019.
77 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q4 2021.

Based on Capital Asset Advisory Services's 13F filing for Q4 2021, filed 4 Feb 2022.